Prevention of Traveler's Diarrhea while Crossing the Amazon Rainforest by Bike with a Supplement Based on Lacticaseibacillus Rhamnosus LR04 (DSM 16605) + Streptococcus Thermophilus FP4 (DSM 18616) + Bifidobacterium Brevis BR03 (DSM 16604): a Phase Two, Randomized, Placebo-controlled, Double-blind, Cross-over Pilot Study
Top Italian Scientists Journal · 2025
DOI: 10.62684/bysu4717 ↗Kurz gefasst
Fachartikel in der Zeitschrift Top Italian Scientists Journal, 2025. Verfasst von Alberto Vaona und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Traveler's diarrhea is a common gastrointestinal illness experienced by individuals traveling to countries with inadequate sanitation and hygiene standards. In this Phase Two, Randomized, Placebo-controlled, Double-blind, Cross-over Pilot Study, we aimed to explore whether a probiotic containing Lacticaseibacillus rhamnosus LR04 (DSM 16605) + Streptococcus thermophilus FP4 (DSM 18616) + Bifidobacterium breve BR03 (DSM 16604) could prevent traveler’s diarrhea and improve quality of life over three months of follow-up in a cohort of athletes biking though the Amazon rainforest. In this pilot study including 3 cyclists randomly assigned to one of the two experimental groups (one probiotic, one placebo). The three participants were men aged 47, 63, 64 years. During the follow-up period, we observed one episode of diarrhea in the probiotic group and one in placebo (p=1.00). However, the number of days with diarrhea was only two in the active group and seven in the placebo group (p=0.33). No episodes of severe diarrhea were observed during the follow-up. At the end of the study, the active group showed a higher quality of life, but no statistically significant. In conclusion, our study suggests that the supplementation with Lacticaseibacillus rhamnosus LR04 (DSM 16605) + Streptococcus thermophilus FP4 (DSM 18616) + Bifidobacterium breve BR03 (DSM 16604) may help prevent traveler’s diarrhea in extreme conditions such as to biking through the Amazon rainforest. However, future larger studies involving a more general population are needed to confirm our findings.
Zitieren
APA
Vaona, A., Amoruso, A., Pane, M., & Veronese, N. (2025). Prevention of Traveler's Diarrhea while Crossing the Amazon Rainforest by Bike with a Supplement Based on Lacticaseibacillus Rhamnosus LR04 (DSM 16605) + Streptococcus Thermophilus FP4 (DSM 18616) + Bifidobacterium Brevis BR03 (DSM 16604): a Phase Two, Randomized, Placebo-controlled, Double-blind, Cross-over Pilot Study. Top Italian Scientists Journal. https://doi.org/10.62684/bysu4717
Vancouver
Vaona A, Amoruso A, Pane M, Veronese N. Prevention of Traveler's Diarrhea while Crossing the Amazon Rainforest by Bike with a Supplement Based on Lacticaseibacillus Rhamnosus LR04 (DSM 16605) + Streptococcus Thermophilus FP4 (DSM 18616) + Bifidobacterium Brevis BR03 (DSM 16604): a Phase Two, Randomized, Placebo-controlled, Double-blind, Cross-over Pilot Study. Top Italian Scientists Journal. 2025. doi:10.62684/bysu4717
BibTeX
@article{Vaona2025,
author = {Vaona, Alberto and Amoruso, Angela and Pane, Marco and Veronese, Nicola},
title = {Prevention of Traveler's Diarrhea while Crossing the Amazon Rainforest by Bike with a Supplement Based on Lacticaseibacillus Rhamnosus LR04 (DSM 16605) + Streptococcus Thermophilus FP4 (DSM 18616) + Bifidobacterium Brevis BR03 (DSM 16604): a Phase Two, Randomized, Placebo-controlled, Double-blind, Cross-over Pilot Study},
journal = {Top Italian Scientists Journal},
year = {2025},
doi = {10.62684/bysu4717}
}
EUVIMED